Statins in chronic kidney disease: what do meta-analyses tell us?

Related Experiment Video

Updated: May 6, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

Ashish Upadhyay1

  • 1Section of Nephrology, Boston Medical Center, Boston University School of Medicine, 72 East Concord Street, Evans Building, Suite 124, Boston, MA, 02118, USA, ashishu@bu.edu.

Clinical and Experimental Nephrology
|October 26, 2013
PubMed

Insights

Statin therapy effectively reduces mortality and cardiovascular events in chronic kidney disease (CKD) patients not on dialysis. However, evidence for statins in dialysis patients is limited, with no proven benefit for kidney function or failure risk.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Pharmacology

Background:

  • Dyslipidemia is prevalent in chronic kidney disease (CKD) patients.
  • Many CKD patients with dyslipidemia do not receive guideline-recommended statin therapy.
  • Previous reports highlight a gap in statin utilization for CKD-related dyslipidemia.

Purpose of the Study:

  • To review recent meta-analyses on statin therapy in CKD patients.
  • To summarize evidence regarding hard clinical outcomes and adverse events associated with statin use in CKD.
  • To evaluate the efficacy of statins in non-dialysis-dependent CKD versus dialysis-dependent CKD populations.

Main Methods:

  • Review of two recent meta-analyses synthesizing data from randomized controlled trials (RCTs).
  • Focus on RCTs reporting hard clinical outcomes (e.g., mortality, cardiovascular events).
  • Analysis of major adverse events and kidney-specific outcomes (kidney failure, function decline).

Main Results:

  • Statin therapy demonstrated safety and efficacy in reducing mortality and major cardiovascular events for non-dialysis-dependent CKD patients.
  • Limited evidence supports statin use in patients undergoing dialysis.
  • Statin therapy did not significantly reduce the risk of kidney failure or decline in kidney function in the studied populations.

Conclusions:

  • Statin therapy is beneficial for cardiovascular risk reduction in non-dialysis CKD patients.
  • Current evidence does not support routine statin use for renal protection or in dialysis patients.
  • Further research is needed to clarify the role of statins in dialysis-dependent CKD.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

15.4K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
706
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.4K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275